Structure Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Structure Therapeutics Inc. (GPCR) reported Increase (Decrease) in Prepaid Expense and Other Assets of $5.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.72M, a 4493.55% decline year-over-year.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $7.99M, a 58.27% increase year-over-year.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $9.13M.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $2.18M.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $16.41M, a 1065.70% increase from fiscal 2024.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.41M, a 65.12% decline from fiscal 2023.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $4.04M, a 1223.61% increase from fiscal 2022.
- Structure Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $305.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.26M 10-Q · filed 2026-08-06 | $14.39M derived: sum of 3 quarters · filed 2026-08-06 | $16.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.99M 10-Q · filed 2026-05-07 | $17.11M derived: sum of 2 quarters · filed 2026-05-07 | $19.29M derived: sum of 3 quarters · filed 2026-05-07 | $19.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.30M derived: sum of 2 quarters · filed 2026-02-26 | $11.37M derived: sum of 3 quarters · filed 2026-08-06 | $16.41M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.24M derived: sum of 2 quarters · filed 2026-08-06 | $7.29M 10-Q · filed 2025-11-06 | $6.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.11M 10-Q · filed 2026-08-06 | $4.44M derived: sum of 3 quarters · filed 2026-08-06 | $2.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.05M 10-Q · filed 2026-05-07 | $4.38M derived: sum of 2 quarters · filed 2026-05-07 | $2.24M derived: sum of 3 quarters · filed 2026-05-07 | -$171.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.81M derived: sum of 2 quarters · filed 2026-02-26 | -$5.22M derived: sum of 3 quarters · filed 2026-02-26 | $1.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.55M derived: sum of 2 quarters · filed 2025-11-06 | $2.08M 10-Q · filed 2025-11-06 | $3.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.22M 10-Q · filed 2025-08-06 | $5.97M derived: sum of 3 quarters · filed 2026-02-26 | $6.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.63M 10-Q · filed 2025-05-08 | $8.38M derived: sum of 2 quarters · filed 2026-02-26 | $9.28M derived: sum of 3 quarters · filed 2026-02-26 | $7.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.65M derived: sum of 2 quarters · filed 2026-02-26 | $992.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.04M 10-K · filed 2026-02-26 |
| 2023-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$758.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.29M 10-Q · filed 2024-11-13 | $2.52M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.39M 10-Q · filed 2024-08-08 | $1.62M derived: sum of 3 quarters · filed 2024-08-08 | $702.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.04M 10-Q · filed 2024-05-09 | $3.28M derived: sum of 2 quarters · filed 2024-05-09 | $2.36M derived: sum of 3 quarters · filed 2024-05-09 | $3.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$685.00K derived: sum of 2 quarters · filed 2024-03-08 | $208.00K derived: sum of 3 quarters · filed 2024-03-08 | $305.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$917.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | -$24.00K derived: sum of 2 quarters · filed 2023-11-17 | $73.00K 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $893.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $990.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $97.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |